



ATTORNEY DOCKET NO.: 0492479-0033 (MGH 2231)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Xudong HUANG	Examiner:	NYA
Serial No.:	10/762,965	Art Unit:	NYA
Filing Date:	January 22, 2004		
Title:	Amyloid-Binding, Metal-Chelating Agents		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Express Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Feb. 4, 2005

Date

Aveline

Signature

Beatrice M. Aveline, Ph.D.

Typed or Printed Name of person signing certificate

Sir:

TRANSMITTAL LETTER


Enclosed are the following documents:

1. Form PTO-1449 (**3** pages);
2. Information Disclosure Statement (**6** pages);
3. Cited Art (**15**); and
4. Return Postcard.

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721

Respectfully submitted,

Dated: 2/4/2005


Brenda Herschbach Jarrell, Ph.D.
Registration No.: 39,223

CHOATE, HALL & STEWART LLP
Exchange Place
53 State Street
Boston, MA 02109
(617) 248-5000
(617) 248-4000



ATTORNEY DOCKET NO.: 0492479-0033 (MGH 2231)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Xudong HUANG	Examiner:	NYA
Serial No.:	10/762,965	Art Unit:	NYA
Filing Date:	January 22, 2004		
Title:	Amyloid-Binding, Metal-Chelating Agents		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as Express Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Feb. 4, 2005

Aveline

Beatrice M. Aveline, Ph.D.

Typed or Printed Name of person signing certificate

Sir:

STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

- An *original* Information Disclosure Statement; or
 A *supplemental* Information Disclosure Statement.

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

- [X] Pursuant to 37 CFR § 1.97(b); no fee or certification is required:
- [] Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);
- [] Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;
- [X] Before the mailing of a first Office action on the merits; or
- [] Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.
- [] Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *either*:
- [] Certifies that *either*:
- [] each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
- [] That no item of information contained in the information disclosure statement was cited in a communication from a foreign

patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; or

- [] Includes herewith the fee set forth in § 1.17(p).
- [] Pursuant to 37 CFR § 1.97(d), after the mailing date of any final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *both*:
- [] Certifies that *either*:
- [] each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
- [] That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of

the information disclosure statement.; and

- [] Includes herewith the fee set forth in § 1.17(p).

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- [X] A copy of each cited reference not indicated with an asterisk is included;
- [] Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status

- [] Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

- [X] Does not contain non-English language citations;

- [] Does contain non-English language citations, for which an English language abstract is submitted.
- [] Does contain non-English language citations which were cited on an International Search Report (a copy of which is enclosed herewith).
- [] Includes one or more translations of a non-English citation.

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b) .

The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,

Dated: 4/1/2005



Brenda Herschbach Jarrell, Ph.D.
Registration No. 39,223

CHOATE, HALL & STEWART LLP
Exchange Place
53 State Street
Boston, MA 02109
(617) 248-5000
(617) 248-4000

115

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 0492479-0033	In Re Application No.: 10/762,965	
			Applicant: Xudong HUANG		
			Filing Date: January 22, 2004	Group:	
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>					

U.S. PATENT DOCUMENTS

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
	* 4,434,151	Byrne <i>et al.</i>	February 28, 1984	424	1.1
	* 4,444,690	Fritzberg	April 24, 1984	260	429
	* 4,670,545	Fritzberg <i>et al.</i>	June 2, 1987	534	14
	* 4,673,562	Davison <i>et al.</i>	June 16, 1987	424	1.1
	* 4,687,659	Quay	August 18, 1987	424	9
	* 4,708,716	Sibalis	November 24, 1987	604	20
	* 4,885,363	Tweedle	December 5, 1989	540	465
	* 4,897,255	Fritzberg <i>et al.</i>	January 30, 1990	424	1.1
	* 4,933,156	Quay <i>et al.</i>	June 12, 1990	424	1.1
	* 4,965,392	Fritzberg <i>et al.</i>	October 23, 1990	558	254
	* 4,980,147	Fritzberg <i>et al.</i>	December 25, 1990	424	1.1
	* 4,988,496	Srinivasan <i>et al.</i>	January 29, 1991	424	1.1
	* 5,008,099	Quay <i>et al.</i>	April 16, 1991	424	1.1
	* 5,021,556	Srinivasan <i>et al.</i> ,	June 4, 1991	534	10
	* 5,039,511	Quay <i>et al.</i>	August 13, 1991	424	1.1
	* 5,075,099	Srinivasan <i>et al.</i>	December 24, 1991	424	1.1
	* 5,087,440	Cacheris <i>et al.</i>	February 11, 1992	424	9
	* 5,155,215	Ranney	October 13, 1992	534	16
	* 5,188,816	Sherry <i>et al.</i>	February 23, 1993	424	9
	* 5,219,553	Kraft <i>et al.</i>	June 15, 1993	424	9
	* 5,262,532	Tweedle <i>et al.</i>	November 16, 1993	540	145
	* 5,277,895	Platzek <i>et al.</i>	January 11, 1994	424	9
	* 5,358,704	Desreux <i>et al.</i>	October 25, 1994	424	9
	* 5,372,579	Sibalis	December 13, 1994	604	20
	* 5,410,043	Platzek <i>et al.</i>	April 25, 1995	540	465
	* 5,559,214	Delecki <i>et al.</i>	September 24, 1996	534	10
	* 6,114,175	Klunk <i>et al.</i>	September 5, 2000	436	63
	* 6,133,259	Klunk <i>et al.</i>	October 17, 2000	514	230.5

FORM PTO-1449 (REV. 8-83)		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket: 0492479-0033	In Re Application No.: 10/762,965
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant: Xudong HUANG			
		Filing Date: January 22, 2004	Group:		
	* 6,150,376	Kozikowski	November 21, 2000	514	299
	* 6,168,776	Klunk <i>et al.</i>	January 2, 2001	424	1.11
	* 6,323,218	Bush <i>et al</i>	November 27, 2001	514	311
U.S. PATENT APPLICATIONS					
Examiner's Initials:	Serial Number:	Applicant:	Publication Date:	Group:	Art Unit:
FOREIGN PATENT DOCUMENTS					
Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No
	WO 94/08624	International	April 28, 1994		✓
	WO 94/08629	International	April 28, 1994		✓
	WO 94/09056	International	April 28, 1994		✓
.	WO 94/12216	International	June 9, 1994		✓
.	WO 94/13327	International	June 23, 1994		✓
.	WO 94/29333	International	December 22, 1994		✓
.	WO 95/26754	International	October 12, 1995		✓
.	WO 97/41856	International	November 13, 1997		✓
.	WO 02/28441	International	April 11, 2002		✓
.	WO 02/085903	International	October 31, 2002		✓
.	EP 0 681 844	European	November 15, 1995		✓
OTHER DOCUMENTS					
Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)				
	Bacska et al., "Imaging amyloid-beta deposits in vivo", Journal of Cerebral Blood Flow and Metabolism, 2002, 22(9)" 1035-1041				
	Poduslo et al., "Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging", Neurobiology of Disease, 2002, 11(2; 315-329				
	Wang et al., "Synthesis and Evaluation of 2-(3'-iodo-4'-aminophenyl)-6-hydrobenzothiazole for in vivo quantitation of amyloid deposits in Alzheimer's disease", J. Mol. Neurosc., 2002, 19(1-2): 11-16				
	Wang et al., "Synthesis and 11C-Labeling of (E,E)-1(3',4'-dihydroxystyryl)-4-(3'-methoxy-4'-				

FORM PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket: 0492479-0033	In Re Application No.: 10/762,965
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant: Xudong HUANG	
		Filing Date: January 22, 2004	Group:
		hydroxystyryl) benzene for PET imaging of amyloid deposits", Journal of Labelled Compounds and Radiopharmaceuticals, 2002, 45(8): 647-664	
EXAMINER	DATE CONSIDERED		
<p>.EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			